Market Overview:
The global mydriatic eyedrops market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of eye disorders, rising awareness about eye care, and technological advancements in the field of ophthalmology. Based on type, the global mydriatic eyedrops market is segmented into atropine, homatropine, dolly, and others. The atropine segment is expected to account for the largest share of the global mydriatic eyedrops market in 2018. This segment is also projected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030 due to its high efficacy and safety profile. Based on application, the global mydriatic eyedrops market is divided into adult and children segments. The adult segment accounted for majority share of this market in 2017 and is projected to grow at a CAGR of 5% duringthe forecast period from 2018to 2030 owingto an increasein demandfor better treatment optionsfor variouseye disordersamong adults worldwide .
Product Definition:
Mydriatic eyedrops are used to dilate the pupil of the eye. This is done in order to allow for a better view of the inside of the eye, and to help diagnose certain eye conditions. Mydriatic eyedrops can also be used to treat glaucoma.
Atropine:
Atropine is a tropane alkaloid that is found in the medicinal plant belladonna. Atropine acts as an anticholinergic drug and blocks the release of acetylcholine, a chemical messenger that facilitates nerve excitation. It also inhibits the parasympathetic nervous system which controls bladder function and respiration.
Homatropine:
Homatropine is a tropane alkaloid and is found in the medicinal plant Asclepias syriaca. It has potent anticholinergic, anti-inflammatory and local anesthetic properties. The drug has been used in traditional medicines to treat cold symptoms, gastrointestinal conditions as well as eye drops for mydriatic (making them itchy) effect.
The global eyedrops market was valued at USD 469 million in 2016.
Application Insights:
The adult segment held the largest share of over 70.0% in 2017. The application of mydriatic eyedrops is most commonly found in patients suffering from glaucoma, ocular allergies, and other eye diseases such as iritis or uveitis. In addition, a growing number of patients with moderate to severe dry eyes is expected to contribute towards market growth during the forecast period.
Glaucoma is one of the leading causes for blindness worldwide and was estimated to affect nearly 7 million people across the globe in 2016 according to data published by IASO International Association for Prevention & Detection of Eye Diseases (IAPB). Growing awareness about this disease coupled with increasing availability of advanced diagnostic tools has led to an increase in its incidence over recent years which is anticipated to boost demand for mydriatic eyedrops during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. Increasing prevalence of eye diseases, growing geriatric population, and high adoption of modern healthcare facilities are some major factors contributing to the growth of this regional market. In addition, presence of key players such as Bausch & Lomb and Allergan plc., with extensive distribution networks is also supporting the growth in North America eyedrops market.
Growth Factors:
- Increasing prevalence of eye disorders: The increasing prevalence of various eye disorders is one of the key growth drivers for the mydriatic eyedrops market. According to a study by The National Eye Institute, around 2 million people in the U.S are affected by glaucoma and this number is expected to increase to 3 million by 2020. This will create a high demand for mydriatic eyedrops in order to treat these conditions.
- Rising awareness about eye care: There has been a rising awareness about the importance of eye care in recent years, which is driving people towards using mydriatic eyedrops for better vision and prevention of various eye diseases. This is also contributing significantly towards the growth of this market.
- Technological advancements: The advent of new technologies has led to significant improvements in the design and performance of mydriatic eyedrops, making them more effective and safe than ever before. This is resulting in an increased adoption rate among consumers, thereby propelling market growth further..
Scope Of The Report
Report Attributes
Report Details
Report Title
Mydriatic Eyedrops Market Research Report
By Type
Atropine, Homatropine, Dolly, Others
By Application
Adult, Children
By Companies
Novartis AG, Allergan, Inc., Meda Pharmaceuticals Inc, Bausch & Lomb Inc, Cigna, Similasan Corporation, Visine, Alcon, Viva Opti-Free, Bausch & Lomb, Systane, Rite Aid, Walgreens, Staples, Clear eyes
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Mydriatic Eyedrops Market Report Segments:
The global Mydriatic Eyedrops market is segmented on the basis of:
Types
Atropine, Homatropine, Dolly, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adult, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis AG
- Allergan, Inc.
- Meda Pharmaceuticals Inc
- Bausch & Lomb Inc
- Cigna
- Similasan Corporation
- Visine
- Alcon
- Viva Opti-Free
- Bausch & Lomb
- Systane
- Rite Aid
- Walgreens
- Staples
- Clear eyes
Highlights of The Mydriatic Eyedrops Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Atropine
- Homatropine
- Dolly
- Others
- By Application:
- Adult
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mydriatic Eyedrops Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mydriatic eyedrops are a type of medication that dilate the pupil (the black part of the eye) in order to make it easier to see in low light or during night time. Mydriatics are used to treat conditions such as glaucoma, myopia (nearsightedness), and cataracts.
Some of the major companies in the mydriatic eyedrops market are Novartis AG, Allergan, Inc., Meda Pharmaceuticals Inc, Bausch & Lomb Inc, Cigna, Similasan Corporation, Visine, Alcon, Viva Opti-Free, Bausch & Lomb, Systane, Rite Aid, Walgreens, Staples, Clear eyes.
The mydriatic eyedrops market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Mydriatic Eyedrops Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Mydriatic Eyedrops Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Mydriatic Eyedrops Market - Supply Chain
4.5. Global Mydriatic Eyedrops Market Forecast
4.5.1. Mydriatic Eyedrops Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Mydriatic Eyedrops Market Size (000 Units) and Y-o-Y Growth
4.5.3. Mydriatic Eyedrops Market Absolute $ Opportunity
5. Global Mydriatic Eyedrops Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Mydriatic Eyedrops Market Size and Volume Forecast by Type
5.3.1. Atropine
5.3.2. Homatropine
5.3.3. Dolly
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Mydriatic Eyedrops Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Mydriatic Eyedrops Market Size and Volume Forecast by Application
6.3.1. Adult
6.3.2. Children
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Mydriatic Eyedrops Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Mydriatic Eyedrops Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Mydriatic Eyedrops Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Mydriatic Eyedrops Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Mydriatic Eyedrops Demand Share Forecast, 2019-2029
9. North America Mydriatic Eyedrops Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Mydriatic Eyedrops Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Mydriatic Eyedrops Market Size and Volume Forecast by Application
9.4.1. Adult
9.4.2. Children
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Mydriatic Eyedrops Market Size and Volume Forecast by Type
9.7.1. Atropine
9.7.2. Homatropine
9.7.3. Dolly
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Mydriatic Eyedrops Demand Share Forecast, 2019-2029
10. Latin America Mydriatic Eyedrops Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Mydriatic Eyedrops Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Mydriatic Eyedrops Market Size and Volume Forecast by Application
10.4.1. Adult
10.4.2. Children
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Mydriatic Eyedrops Market Size and Volume Forecast by Type
10.7.1. Atropine
10.7.2. Homatropine
10.7.3. Dolly
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Mydriatic Eyedrops Demand Share Forecast, 2019-2029
11. Europe Mydriatic Eyedrops Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Mydriatic Eyedrops Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Mydriatic Eyedrops Market Size and Volume Forecast by Application
11.4.1. Adult
11.4.2. Children
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Mydriatic Eyedrops Market Size and Volume Forecast by Type
11.7.1. Atropine
11.7.2. Homatropine
11.7.3. Dolly
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Gowth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Mydriatic Eyedrops Demand Share, 2019-2029
12. Asia Pacific Mydriatic Eyedrops Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Mydriatic Eyedrops Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Mydriatic Eyedrops Market Size and Volume Forecast by Application
12.4.1. Adult
12.4.2. Children
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Mydriatic Eyedrops Market Size and Volume Forecast by Type
12.7.1. Atropine
12.7.2. Homatropine
12.7.3. Dolly
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Mydriatic Eyedrops Demand Share, 2019-2029
13. Middle East & Africa Mydriatic Eyedrops Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Mydriatic Eyedrops Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Mydriatic Eyedrops Market Size and Volume Forecast by Application
13.4.1. Adult
13.4.2. Children
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Mydriatic Eyedrops Market Size and Volume Forecast by Type
13.7.1. Atropine
13.7.2. Homatropine
13.7.3. Dolly
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Mydriatic Eyedrops Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Mydriatic Eyedrops Market: Market Share Analysis
14.2. Mydriatic Eyedrops Distributors and Customers
14.3. Mydriatic Eyedrops Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Allergan, Inc.
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Meda Pharmaceuticals Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bausch & Lomb Inc
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cigna
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Similasan Corporation
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Visine
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Alcon
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Viva Opti-Free
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Bausch & Lomb
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Systane
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Rite Aid
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Walgreens
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Staples
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Clear eyes
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
